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Abstract
Background: A major problem in cost-effectiveness studies is where to draw the line between
interventions which are cost-effective and those who are not. Lacking a notion about the value of
a QALY, all ultimate values to the cost-effectiveness ratio are essentially arbitrary.
Methods: This paper presents a simple empirical model to estimate the compensating income
variation of diseases and health problems. The model is estimated using data for the Netherlands.
Results: The compensating income variation is between €20,000 and €90,000. This is higher than
most of the ultimate values used by policy-makers to decide whether an intervention is cost-
effective. Our figures are roughly similar to those found in studies about the value of a statistical
life year.
Conclusion: Estimates on the compensating income variation of diseases and health problems may
provide useful information on the maximum acceptable cost-effectiveness ratio of medical
interventions than those currently used by policy makers.
Background
Western countries spend an increasing share of income on
health care. Where forty years ago western European
countries and the United States spent 4–5% of GDP on
health care, they nowadays spend 10% or more. The rapid
increase in expenditures has fostered the need for more
rational decision making in health care and hence the
emergence of cost-effectiveness (CEA) and cost-utility
analysis (CUA). A typical problem with both CEA and
CUA, however, is where to draw the line between medical
interventions which are welfare improving and those
which are not. Some countries have informal rules about
the maximum cost per QALY. In the Netherlands inter-
ventions with a cost per QALY of less than €20,000 are
thought to be efficient. In Great Britain, the National Insti-
tute of Clinical Excellence (NICE) does not use a specific
cost per QALY threshold above which a technology is
rejected. However, NICE uses a band of approximately
£20,000 – £30,000 "... as the threshold above which it
would be increasingly likely to reject a technology on
grounds of its cost-ineffectiveness" [[1]; p.2619]. Recently
a Dutch government advisory board recommended
putting the border at €80,000 per QALY [2]. All these fig-
ures are essentially arbitrary. What is required is a notion
about how much individuals value a QALY or a life year
saved. Only then can we decide whether medical interven-
tions are truly welfare improving.
Few studies have tried to quantify the value of the health
benefits obtained by medical technologies. These studies
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invariably conclude that the benefits of health care out-
weigh its costs. Murphy & Topel [3] find that the cumula-
tive value of improvements in life expectancy in recent
decades exceeds $3 trillion per year, much more than the
annual health care expenditures. For an individual Amer-
ican, the increase in life expectancy in the twentieth cen-
tury amounted to $1.2 million by the year 2000. Cutler &
Richardson [4] estimate that – even if only a quarter of the
overall improvement in health can be attributed to medi-
cal care – health care expenditures are worth the cost. Cut-
ler & Meara [5] estimate that between 1950 and 1990 the
costs of postnatal care increased by nearly $40,000 and
the net benefits of treatment increased by nearly $200,000
per low-birth infant. Cutler & Huckman [6] estimate the
costs and benefits of percutaneous transluminal coronary
angioplasty (PTCA) and find that the net benefit is
between $19,000 and $22,000 per additional PTCA.
Other studies have estimated the cost-benefit of medical
expenditures by calculating the compensating income var-
iation of health impairments, i.e. the income needed to
make someone with a health impairment as well off as
someone without in good health. Groot, Maassen van den
Brink & Plug [7] and Groot & Maassen van den Brink [8,9]
find that cardiovascular disease has a major negative
impact on quality of life. These studies calculate that the
compensating income variation is substantial and higher
than the costs of most medical treatment for this disease.
Groot & Maassen van den Brink [9] use data from the Brit-
ish Household Panel Survey and find that at the average
values of household income, the compensating income
variation of cardiovascular disease is approximately
£49,000 for both men and women. These values are
broadly similar to the amounts calculated for cardiovascu-
lar disease in Groot, Maassen van den Brink & Plug [7]
using data for the Netherlands.
This paper builds on this research on separate diseases
and uses data on subjective well-being to calculate the
welfare effects – the compensating income variation – of
various diseases and health impairments. Essentially the
approach we take in this paper is based on an evaluation
by respondents of their subjective well-being, individual
level data on the prevalence of handicaps and diseases,
and household income. Subjective well-being is assumed
to depend – among others – on net household income
and the health status. The estimation results are used to
calculate the income-health trade-off, keeping well-being
constant. This income-health trade-off – or compensating
income variation – represents the monetary value of a
health gain and can be interpreted as the willingness-to-
pay for the elimination of a disease or handicap.
Measures of subjective well-being are widely used in psy-
chology and social sciences, and increasingly also among
economists. Krueger & Schkade [10] note that between
2000 and 2007 more than 150 papers and books have
been published using data on life satisfaction or subjec-
tive well-being. The use of these direct measures of well-
being is stimulated by findings that show that data on life
satisfaction have good reliability [10] and validity [11,12].
However, questions about subjective well-being can be
phrased in different ways. In some surveys respondents
are asked how happy they are, others ask about satisfac-
tion with life in general or with certain domains of life.
Even if data on subjective well-being have good reliability
and validity, the outcomes may be affected by the way
these questions are phrased. In this paper we therefore use
two different questions on subjective well-being: one
about happiness and one about life-satisfaction. A com-
parison between the outcomes of these two will contrib-
ute to establishing the validity of our findings.
Methods
The starting point of the empirical model is the subjective
well-being function (W*). In the empirical application we
operationalize subjective well-being by survey questions
on happiness and life satisfaction. Well-being is assumed
to be a cardinal variable. We feel justified in doing so by
the findings of Ferrer-i-Carbonell & Frijters [13] who con-
clude that assuming ordinality or cardinality of happiness
makes little difference. It is assumed that well-being of
individual i is determined by income Y, health status H
and other individual characteristics X:
Wi* = W(Yi, Hi, Xi)( 0 . 1 )
where Y is the net annual household income. We assume
that well-being is a linear function of the log of household
income, health status and other individual characteristics:
Wi* = β0 + β1LogYi+ β2Hi+ β3Xi+ ηi (0.2)
where  β are coefficients that measure the impact of
income and other characteristics on well-being and η is a
normally distributed random error term capturing
unmeasured and unmeasurable effects on well-being. The
log of income is used instead of income itself in order to
take account of the established fact of diminishing mar-
ginal utility of income (Using the log of income also pro-
vided more precise estimates of the income effect than
using the level of income in our dataset) (see [14-18]).
The parameter estimates are used to calculate the compen-
sating income variation (CIV) of health impairments, i.e.
the additional amount of money needed to make some-
one with a health problem as well off as someone without
these problems.BMC Health Services Research 2008, 8:136 http://www.biomedcentral.com/1472-6963/8/136
Page 3 of 9
(page number not for citation purposes)
Someone with a health problem (H = 1) enjoys the same
welfare as someone without these problems (H = 0) if:
W*(LogY, Hi= 0, Xi) = W*(LogYi+ LogCIVi, Hi= 1, Xi)
(0.3)
Substitution in the specification of the equation for well-
being above, this translates into:
This gives the CIV as the increase in annual net household
income.
The data are taken from the 2004 Periodic Life Style Sur-
vey (PLSS) of the Dutch Central Bureau of Statistics (The
data are stored as file P1665 at the Data Archiving and
Networked Services (DANS) [28]) The PLSS is an annual
cross-sectional survey of the population of all ages in the
Netherlands. The PLSS consists of various modules. All
respondents (N = 21,706) receive a basic questionnaire
containing demographic and socio-economic questions
including income and questions about life situation
(including happiness and life satisfaction). The question-
naires for the different modules of the survey are pre-
sented to a selection of the respondents. For our purposes
we combine information from the basic questionnaire
with the survey on health and labour (N = 11,117). The
module on health and labour includes detailed informa-
tion about the prevalence of diseases and health impair-
ments. The response rate of the basic questionnaire is
59.9%, while the response rate of the health and labour
module is 61.4%. We restrict the sample to people aged
16 and older and use information of respondents who
have completed both the basic questionnaire and those
on labour and health. This restricts the sample to approx-
imately 6,800 respondents.
One advantage of using subjective well-being measures to
calculate the CIV of health impairments is that the cogni-
tive burden on respondents is lower than with other tech-
niques. According to Diener & Suh [[12], p.437], 'When
self-reports of well-being are correlated with other meth-
ods of measurement, they show adequate convergent
validity.' Krueger & Schkade [10] draw similar conclusions
for the reliability of subjective well-being measures.
Diener & Suh [11] assert that the major advantage of the
subjective well-being measures is '(...) that they capture
experiences that are important to the individual' (p. 205).
As a major disadvantage they note that 'although self-
reported measures of well-being have adequate validity
and reliability, it is naive to assume that every individual's
responses are totally valid and accurate' (p. 206). Their
review further shows that there is a high correlation
between life satisfaction and a social index that includes
cost of living, ecology, health, culture and entertainment,
freedom and infrastructure indicators. Diener & Shuh
[11,12] further assert that life satisfaction measures are
found to be stable over time and across countries.
We use two measures of subjective well-being: one on
happiness and one on life satisfaction. The happiness var-
iable is defined by the response to the following survey
question: "To what extent do you consider yourself a
happy person?" there are five answering categories:
Unhappy; Not so happy; Not happy, not unhappy;
Happy; and Very happy. Life satisfaction is measured by
the response to the following question: "To what extent
are you satisfied with the life you now lead?" Again, there
are five answering categories: Not so satisfied; Rather sat-
isfied; Satisfied; Very satisfied; and Extremely satisfied.
A comparison between the happiness and life-satisfaction
variable shows that the happiness variable has two nega-
tive answering categories (unhappy and not so very
happy), while life satisfaction has only one (not so satis-
fied). The life satisfaction variable, on the other hand, has
more positive options (very satisfied and extremely satis-
fied) than the happiness variable (very happy).
Results
Table 1 contains the frequency distribution of the answers
to the happiness and life satisfaction questions. Nearly
90% of all respondents say they are happy or very happy,
while only less than 3% report to be not so very happy or
unhappy. Similarly, more than 80% of all respondents say
they are satisfied or very satisfied with their life and only
less than 4% say there are not so satisfied. Differences
between men and women in both happiness and life sat-
isfaction ratings appear to be small.
For the health impairment variables, H, the response to a
battery of survey questions on health status is used. Table
2 presents the variable description and the sample means
for the health variables, income and the control variables
in the equations. The summary statistics in Table 2 show
that 1.4% of the men and 1.3% of the women in our sam-
ple ever had cancer, while 2.1% of the men and 1.8% of
the women have had heart problems during the past 12
months. The most prevalent health problems during the
past 2 months are a cold or influenza and diarrhea. High
blood pressure and serious back problems are the most
prevalent health impairments during the past 12 months.
Income refers to after tax household income. Net house-
hold income is computed by summing up all wage and
non-wage income received by all income earners in the
household.
CIV Y Y ii i =− − exp( )
β
β
2
1
(0.4)BMC Health Services Research 2008, 8:136 http://www.biomedcentral.com/1472-6963/8/136
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The ordered probit estimates on happiness and life satis-
faction are found in table 3. We present separate estimates
for men and women and for the entire sample. The results
show that only few of the health variables have a statisti-
cally significant effect on happiness or life satisfaction.
Typically, we find no significant effects of major health
problems as stroke, heart attack or cancer. We do, how-
ever, find that diabetes, dizziness with falling, influenza,
problems with elbow, wrist or hand, and migraine have a
substantially negative effect on both happiness and life
satisfaction.
This absence of a systematic effect of severe health impair-
ments on subjective well-being is probably caused by the
lack of sufficient 'positive' observations: there are too few
respondents with these health problems to generate statis-
tically significant results. To increase the precision of our
estimates we have reduced the number of health condi-
tions by running a factor analysis on the 27 health impair-
ments variables. Nine factors were extracted. We have
used these nine factors to define nine disease categories by
including variables with a factor loading of 0.4 or more.
The nine disease categories are defined as:
- Disease category 1 includes problems related to move-
ment: serious back problems, wear out of the joints,
arthritis, problems with neck or shoulder and problems
with elbow, wrist or hand;
- Disease category 2 includes some chronic disease that
increase the risk of cardiovascular disease: diabetes, high
blood pressure and stricture of blood vessels;
- Disease category 3 are cardiovascular diseases: stroke,
heart attack and heart problems;
- Disease category 4 includes: diarrhea and vomiting;
- Disease category 5 are respiration problems: asthma,
bronchitis, cold or influenza and acute bronchitis;
- Disease category 6 includes cancer and intestine prob-
lems: cancer, serious intestine problems, other long term
disease and infection of kidney or bladder;
- Disease category 7 includes: migraine, dizziness with
falling and involuntary incontinence;
- Disease category 8 includes: ear infection and ulcer;
- Disease category 9 includes: psoriasis and chronic
eczema.
Most of the factors combine diseases which are either
related (f.e. psioriasis and chronic eczema) or can be
symptoms of common causes (f.e. diarrhea and vomit-
ing), or can have common consequences (f.e. diabetes
and high blood pressure) or have in common that they
provide serious discomfort or pain (f.e. ear infection and
ulcer). The estimation results with dummy variables for
these nine groups of health problems are in table 4.
We now find that almost all disease categories have a sta-
tistically significant and negative effect on well-being. The
only exceptions are ear infection and ulcer (category 8)
and psoriasis and chronic eczema (category 9). Cancer
and intestine problems (category 6) and migraine and
dizziness (category 7) have the largest negative effects on
well-being.
The log of household income has a statistically significant
and positive effect on subjective well-being, but the
income effects are relatively small. We find that the
income elasticity with respect to life satisfaction is higher
than the income elasticity of happiness. In the average val-
ues of both variables, the total sample income elasticity of
happiness is 0.043 and the income elasticity of life satis-
faction is 0.120, indicating that a 10% increase in net
household income increases happiness by 0.43% and life
satisfaction by 1.2%. We further find that income elastici-
ties are larger for men than for women, although the dif-
ferences in income effects between men and women are
all within one standard error from eachother. Income
elasticities for happiness are 0.048 for men and 0.040 for
women, while income elasticities of life satisfaction are
0.139 for men and 0.104 for women.
Table 1: Frequency distribution happiness and life satisfaction 
variables
All Men Women
Happiness
Unhappy 0.4% 0.4% 0.4%
Not so very happy 2.5% 2.1% 2.8%
Not happy/not unhappy 7.6% 6.5% 8.6%
Happy 69.0% 71.3% 66.9%
Very Happy 20.6% 19.7% 21.3%
Mean value 4.056 4.069 4.043
# Observations 6792 3261 3531
Life satisfaction
Not so satisfied 3.4% 3.3% 3.6%
Rather satisfied 8.0% 7.0% 8.9%
Satisfied 46.9% 48.8% 45.2%
Very satisfied 33.6% 33.1% 34.2%
Extremely satisfied 8.0% 7.9% 8.1%
Mean value 3.326 3.340 3.312
# Observations 6800 3264 3536BMC Health Services Research 2008, 8:136 http://www.biomedcentral.com/1472-6963/8/136
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We further find a statistically significant and negative
effect of being male on life satisfaction but not on happi-
ness. Age has a U-shaped effect on well-being. Both for the
happiness variable and the life satisfaction variable the
bottom of the age parabola is at age 60. Finally, being
married or living together with a partner has a positive
and substantial effect on subjective well-being.
We use the estimation results of table 4 to calculate the
CIV for every individual in our sample. Table 5 contains
the calculated sample means of the CIV of health impair-
ments.
In general we find that the CIV of health problems based
on the happiness estimates are larger than those calcu-
lated from the life satisfaction estimates. The CIV for
women are also mostly larger than those for men. The
highest CIV are for movement problems (category 1), car-
diovascular problems (category 3), cancer and intestine
problems (category 6) and for migraine and dizziness
(category 7).
Discussion
We find that results for both measures of subjective well-
being – happiness and life satisfaction – are roughly sim-
ilar. Although for a few disease categories estimates vary
widely (f.e. for cardiovascular disease among women the
CIV based on the happiness estimates is much smaller
than the corresponding life satisfaction estimate). The cor-
respondence between the happiness and life satisfaction
estimates gives some confidence in the reliability of the
results. Most effects – for example the income effects – are
more pronounced on life satisfaction than on happiness
however.
Table 2: Variable definition and sample means
Description Men Women
Log income Log annual household income 10.305 10.238
Age Age 45.942 46.554
Marital status Married or cohabiting 0.513 0.487
Urban area Degree of urbanization 3.020 3.010
Have you ever had:
Stroke A celebral haemorrhage, celebral infarct or stroke 0.005 0.002
Heart attack A heart attack 0.005 0.001
Cancer Have you ever had cancer 0.014 0.013
Any diseases Have had stroke heart attack or cancer 0.023 0.016
Did you during the past 12 months have:
Heart problems Heart problems 0.021 0.018
Migraine Migraine or severe headache 0.082 0.193
Diabetes Diabetes 0.042 0.035
High blood pressure High blood pressure 0.108 0.141
Stricture of blood vessels Stricture of blood vessels in belly or legs 0.023 0.020
Asthma, bronchitis Asthma, chronic bronchitis, pulmonary emphysema, or CARA 0.071 0.073
Psoriasis Psoriasis 0.024 0.017
Chronic eczema Chronic eczema 0.036 0.042
Dizziness with falling Dizziness with falling 0.020 0.034
Serious intestine problems Severe or persistent intestine problems for more than 3 months 0.019 0.040
Involuntary incontinence Involuntary incontinence 0.015 0.077
Serious back problems Severe or persistent back problems 0.104 0.116
Wear out of the joints Chronic wear out of joints 0.091 0.148
Arthritis Arthritis 0.032 0.069
Problems with neck or shoulder Condition of neck or shoulder 0.078 0.130
Problems elbow, wrist or hand Condition of elbow, wrist or hand 0.052 0.083
Other long term disease Other long term disease or condition 0.080 0.105
Any disease Any of the diseases listed above during the past 12 months 0.469 0.589
Did you during the past 2 months have:
Cold or influenza A cold, influenza, etc. 0.382 0.412
Acute bronchitis Acute bronchitis or pneumonia 0.018 0.021
Ear infection Ear infection 0.027 0.026
Infection kidney or bladder Infection of kidney or bladder 0.016 0.044
Diarrhea Diarrhea 0.101 0.115
Vomiting Vomiting 0.025 0.041
Ulcer Ulcer 0.012 0.013
Any disease Any of the diseases listed above during the past 2 months 0.462 0.504BMC Health Services Research 2008, 8:136 http://www.biomedcentral.com/1472-6963/8/136
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Income has a statistically significant and positive effect on
life satisfaction for both men and women, as expected.
The size of the effect of income on life satisfaction is rather
small, however. This also explains the relatively large val-
ues for the compensating income variation for health
impairments (see the formulae for the calculation of the
CIV: a smaller value for β1 increases the size of the CIV).
Because of small cell sizes, we were unable to calculate the
compensating income variation for individual diseases
and health problems. Larger data-sets are needed to draw
conclusions on separate diseases and health impairments.
We therefore used factor analysis to classify diseases in
nine broader categories. Unfortunate this may seem, how-
ever for our recommendations about the ultimate values
of the cost-effectiveness of medical intervention this is of
minor importance as policy makers are probably more
interested in values for broad categories of diseases rather
than have separate values for every single disease and
health problem.
Table 3: Ordered probit estimation results on happiness and life satisfaction by gender
All Men Women
Happiness Life satisfaction Happiness Life satisfaction Happiness Life satisfaction
Control variables
Male -0.053 (0.030) -0.077** (0.027)
Log income 0.158** (0.026) 0.208** (0.024) 0.177** (0.039) 0.254** (0.035) 0.145** (0.035) 0.168** (0.033)
Age -0.046** (0.005) -0.036** (0.005) -0.046** (0.007) -0.044** (0.007) -0.047** (0.007) -0.031** (0.006)
Age2/100 0.039** (0.005) 0.034** (0.005) 0.040** (0.007) 0.042 (0.007) 0.038** (0.007) 0.029** (0.006)
Marital status 0.454** (0.036) 0.291** (0.033) 0.476** (0.055) 0.304** (0.050) 0.425** (0.048) 0.285** (0.044)
Urban area -0.001 (0.011) 0.017 (0.010) -0.005 (0.017) 0.006 (0.015) 0.003 (0.016) 0.027 (0.014)
Health variables
Stroke -0.428 (0.247) 0.092 (0.233) -0.334 (0.295) 0.115 (0.276) -0.533 (0.477) 0.092 (0.454)
Heart attack 0.284 (0.275) -0.241 (0.252) 0.157 (0.305) -0.351 (0.279) 0.909 (0.723) -0.082 (0.645)
Heart problems -0.155 (0.105) -0.239** (0.097) -0.278 (0.151) -0.171 (0.139) -0.000 (0.149) -0.284* (0.138)
Cancer -0.097 (0.121) 0.024 (0.112) -0.013 (0.179) 0.145 (0.162) -0.250 (0.168) -0.118 (0.156)
Diabetes -0.250** (0.075) -0.203** (0.069) -0.359** (0.104) -0.204** (0.095) -0.185 (0.110) -0.212* (0.102)
Migraine -0.166** (0.043) -0.123** (0.039) -0.120 (0.078) -0.174* (0.071) -0.180** (0.052) -0.101* (0.048)
High blood pressure -0.064 (0.046) -0.057 (0.042) -0.018 (0.070) -0.037 (0.063) -0.096 (0.060) -0.071 (0.056)
Stricture of blood vessels -0.128 (0.100) -0.215** (0.093) -0.278* (0.144) -0.266* (0.132) -0.006 (0.143) -0.172 (0.133)
Asthma, bronchitis 0.081 (0.058) 0.016 (0.053) 0.057 (0.088) 0.006 (0.080) 0.115 (0.079) 0.048 (0.072)
Psoriasis 0.108 (0.098) 0.010 (0.090) 0.218 (0.137) 0.135 (0.123) -0.027 (0.143) -0.129 (0.133)
Chronic eczema -0.035 (0.074) -0.100 (0.068) -0.018 (0.113) -0.103 (0.102) -0.092 (0.099) -0.122 (0.092)
Dizziness with falling -0.495** (0.091) -0.297** (0.086) -0.592** (0.158) -0.417** (0.149) -0.441** (0.113) -0.225* (0.106)
Serious intestine problems -0.174* (0.086) -0.309** (0.080) -0.170 (0.155) -0.008 (0.142) -0.188 (0.103) -0.440** (0.096)
Involuntary incontinence -0.100 (0.069) -0.123* (0.063) -0.134 (0.175) -0.137 (0.161) -0.062 (0.075) -0.107 (0.070)
Serious back problems -0.192** (0.047) -0.244** (0.043) -0.220** (0.071) -0.253** (0.064) -0.184** (0.064) -0.243** (0.059)
Wear out of the joints -0.029 (0.050) -0.069 (0.045) -0.015 (0.078) -0.046 (0.071) -0.044 (0.065) -0.082 (0.060)
Arthritis 0.052 (0.069) -0.004 (0.063) -0.022 (0.123) -0.113 (0.112) 0.105 (0.084) 0.058 (0.077)
Problems with neck or shoulder -0.056 (0.051) -0.064 (0.046) 0.009 (0.084) 0.016 (0.076) -0.080 (0.064) -0.108 (0.059)
Problems elbow, wrist or hand -0.211** (0.060) -0.214** (0.055) -0.197* (0.097) -0.216* (0.089) -0.226** (0.076) -0.212** (0.070)
Other long term disease -0.139** (0.050) -0.276** (0.046) -0.158* (0.080) -0.267** (0.073) -0.119* (0.064) -0.277** (0.059)
Cold or influenza -0.097** (0.030) -0.056 (0.028) -0.095* (0.045) -0.025 (0.040) -0.105** (0.042) -0.085* (0.039)
Acute bronchitis -0.241* (0.107) -0.180 (0.098) -0.221 (0.167) -0.347* (0.152) -0.242 (0.140) -0.051 (0.130)
Ear infection 0.097 (0.089) 0.121 (0.082) 0.339** (0.130) 0.226 (0.117) -0.122 (0.124) 0.011 (0.115)
Infection kidney or bladder 0.025 (0.083) -0.006 (0.076) 0.072 (0.168) 0.099 (0.153) 0.001 (0.096 -0.047 (0.088)
Diarrhea -0.069 (0.048) -0.050 (0.044) -0.157* (0.072) -0.070 (0.066) -0.000 (0.066) -0.027 (0.060)
Vomiting 0.017 (0.083) -0.048 (0.076) 0.033 (0.147) -0.179 (0.134) 0.039 (0.102) 0.019 (0.094)
Ulcer -0.258* (0.125) -0.130 (0.117) -0.445* (0.184) -0.316 (0.172) -0.059 (0.173) 0.055 (0.165)
Location points
α1 -2.420** (0.295) -0.634 (0.262) -2.189** (0.442) -0.282 (0.387) -2.575** (0.399) -0.907** (0.359)
α2 -1.542** (0.287) 0.040 (0.261) -1.296** (0.429) 0.349 (0.386) -1.686** (0.390) -0.192 (0.358)
α3 -0.834** (0.286) 1.541** (0.262) -0.602 (0.428) 1.932** (0.387) -0.960** (0.388) 1.245** (0.358)
α4 1.375** (0.287) 2.777** (0.263) 1.720** (0.429) 3.159** (0.389) 1.160** (0.388) 2.493** (0.360)
#observations 6792 6800 3261 3264 3531 3536
McFadden R2 0.049 0.035 0.048 0.035 0.052 0.039
* significant at 5% level; ** significant at 1% level.BMC Health Services Research 2008, 8:136 http://www.biomedcentral.com/1472-6963/8/136
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We find that the CIV is approximately €20,000–90,000
depending on the disease category and the measure of
subjective well-being used. These figures suggest that cost-
effective medical interventions are interventions with a
cost per QALY of less than €20,000–90,000. These figures
are higher than the ultimate values used by policy makers
in the Netherlands – where the upper-bound of accepta-
ble cost-effectiveness ratio varies between €18,000 and
€20,000 per QALY [19] – and the United Kingdom –
where the upper-bound is approximately £30,000 or
£43,000 [20] – to decide whether interventions are still
cost-effective.
It should further be noted that few medical interventions
are able to completely cure a disease. If we account for effi-
cacy and the probability that a treatment provides perfect
cure, the discrepancy between the CIV and the maximum
acceptable costs per QALY used by policy makers in their
decisions whether interventions are cost-effective
becomes even larger.
How valid are these estimates? A much used measure for
the value of a QALY is Laupacis et al [21]. This study
argues that the value of a QALY is about $100,000. In a
meta-analysis of 33 studies that have calculated the value
of a statistical life, Mrozek & Taylor [22] infer that the
value of statistical life is $1.5–2.5 million. At a 5% dis-
count rate this would make the value of a statistical life
year between $76,500 and $127,500. Viscusi [23,24] sum-
marizes 24 studies and concludes that the appropriate
range for the value of a statistical life is $4–9 million, as
this is the range in which most estimates lie. In a regres-
sion of 'best estimates' of values of a statistical life year on
a number of characteristics of the studies and countries
included, Miller [25] finds that the value of a statistical life
year is $4 million. Moore & Viscusi [26] estimate that the
value of a statistical life is $5 million. From this latter find-
ing it can be calculated that the properly discounted value
of a statistical life year is about $230.000.
Our estimates are roughly similar to the value of a QALY
inferred by Laupacis et al [21] and the value of a statistical
Table 4: Ordered probit estimation results on happiness and life satisfaction by gender
All Men Women
Happiness Life satisfaction Happiness Life satisfaction Happiness Life satisfaction
Control variables
Male -0.066* (0.029) -0.089** (0.027)
Log income 0.162** (0.026) 0.212** (0.024) 0.181** (0.039) 0.257** (0.035) 0.149** (0.035) 0.174** (0.032)
Age -0.046** (0.005) -0.036** (0.005) -0.046** (0.007) -0.043** (0.007) -0.046** (0.007) -0.031** (0.006)
Age2/100 0.039** (0.005) 0.035** (0.005) 0.041** (0.007) 0.041** (0.007) 0.038** (0.007) 0.029** (0.006)
Marital status 0.457** (0.036) 0.289** (0.033) 0.485** (0.055) 0.301** (0.049) 0.421** (0.048) 0.280** (0.044)
Urban area -0.000 (0.011) 0.019 (0.010) -0.004 (0.017) 0.007 (0.015) 0.003 (0.015) 0.027* (0.014)
Disease category variables
Disease 1 -0.197** (0.034) -0.220** (0.031) -0.180** (0.051) -0.175** (0.046) -0.204** (0.045) -0.252** (0.042)
Disease 2 -0.142** (0.042) -0.137** (0.038) -0.177** (0.062) -0.135** (0.056) -0.115* (0.057) -0.137** (0.053)
Disease 3 -0.153 (0.092) -0.280** (0.085) -0.240 (0.126) -0.243* (0.115) -0.049 (0.137) -0.304* (0.127)
Disease 4 -0.109* (0.044) -0.096* (0.040) -0.191** (0.067) -0.129* (0.061) -0.049 (0.058) -0.071 (0.054)
Disease 5 -0.099** (0.030) -0.067* (0.027) -0.084* (0.043) -0.043 (0.039) -0.114** (0.041) -0.088* (0.038)
Disease 6 -0.158** (0.041) -0.272** (0.038) -0.169** (0.067) -0.221** (0.061) -0.154** (0.053) -0.297** (0.049)
Disease 7 -0.216** (0.038) -0.192** (0.035) -0.240** (0.069) -0.283** (0.063) -0.199* (0.046) -0.150** (0.042)
Disease 8 -0.100 (0.074) -0.010 (0.069) 0.006 (0.108) -0.006 (0.098) -0.189 (0.103) -0.012 (0.096)
Disease 9 0.031 (0.061) -0.059 (0.056) 0.128 (0.090) 0.032 (0.081) -0.064 (0.083) -0.143 (0.077)
Location points
α1 -2.345** (0.293) -0.601* (0.261) -2.084** (0.438) -0.217 (0.385) -2.497** (0.395) -0.869* (0.356)
α2 -1.500** (0.286) 0.063 (0.261) -1.252** (0.427) 0.405 (0.385) -1.638** (0.387) -0.167 (0.355)
α3 -0.802** (0.285) 1.552** (0.261) -0.572 (0.426) 1.975** (0.386) -0.922* (0.385) 1.255** (0.356)
α4 1.392** (0.285) 2.783** (0.262) 1.732** (0.426) 3.193** (0.387) 1.180** (0.386) 2.499** (0.357)
#observations 6866 6874 3291 3294 3575 3580
McFadden R2 0.044 0.032 0.041 0.030 0.048 0.035
* significant at 5% level; ** significant at 1% level. Disease category 1: serious back problems, wear out of the joints, arthritis, problems with neck or 
shoulder and problems with elbow, wrist or hand; Disease category 2: diabetes, high blood pressure and stricture of blood vessels; Disease 
category 3: stroke, heart attack and heart problems; Disease category 4: diarrhea and vomiting; Disease category 5: asthma, bronchitis, cold or 
influenza and acute bronchitis; Disease category 6: cancer, serious intestine problems, other long term disease and infection of kidney or bladder; 
Disease category 7: migraine, dizziness with falling and involuntary incontinence; Disease category 8: ear infection and ulcer; Disease category 9: 
psoriasis and chronic eczema.BMC Health Services Research 2008, 8:136 http://www.biomedcentral.com/1472-6963/8/136
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life year estimates by Mrozek & Taylor [22], but lower
than those calculated from Miller [25], Moore & Viscusi
[26] and Viscusi [23,24].
It should be noted, however, that the theoretical assump-
tions on which the figures on the maximum acceptable
costs per QALY as used by policy makers, the value of a
QALY, the value of a statistical life year and the estimates
of the compensating income variation are based differ.
This limits the comparability of the different values. The
value of a statistical life year and the compensating
income variation are based on strictly welfarist assump-
tions, whereas extra welfarist arguments may influence
the value of a QALY and the maximum acceptable costs
per QALY used by health policy makers. Furthermore, the
value of a statistical life year is usually derived from
observed risk-taking behavior – f.e. through the compen-
sating wage differential for work-related health hazards or
the willingness to pay for safety measures – and are usu-
ally not conditioned on health status.
In our analysis we have ignored the possibility of adapta-
tion and scale of reference bias in the evaluation of subjec-
tive well-being. Adaptation refers to the notion that the
effect of a disease on subjective well-being diminishes
with the duration of the disease, while scale of reference
bias refers to the notion that people compare themselves
with others – for example people of the same age or peo-
ple with the same health problems – in evaluating their
well-being (see [27]). Also, the possibility that some
respondents may be more optimistic while others may be
more pessimistic in the face of a disease or health problem
has been ignored. For example, Groot & Maassen van den
Brink [9] find that that men are relatively more optimistic
and less pessimistic than women in their evaluation of
subjective well-being questions. This study further finds
that cardiovascular disease makes people both less opti-
mistic and less pessimistic.
Conclusion
Cost-effectiveness studies are increasingly used to decide
whether new medical technologies are valuable enough to
merit reimbursement and inclusion in a standard package
of medical services. However, cost-effectiveness studies
are only valuable if we know where to draw the line
between interventions which are cost-effective and those
who are not. The maximum acceptable cost per QALY
used to decide whether a medical intervention is worth-
while is primarily a political decision. If, for political rea-
sons, total public expenditures on health care are limited,
a rational allocation of these limited resources may
require a relatively low maximum acceptable cost per
QALY level. However, from a welfare point of view insight
in the value individuals attach to health and health
improvements may be useful to determine the maximum
acceptable cost per QALY for a medical intervention (and,
by implication, the total resources available for health
care). This paper has estimated the monetary value of
health by the compensating income variation for health
impairments. The results suggest that the ultimate values
of cost-effectiveness ratios used in some countries are
lower than the value people attach to their health.
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